Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab, Endostatin, SOX and Radiotherapy in Gastric Cancer
NCT05387681Phase 2Not yet recruiting
- Start
- May 2022
- Primary completion
- Jul 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of envafolimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoint: Pathological Complete Response at 1 year. Planned start May 2022; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05387681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387681.